Butyric-Cal-Mag[™]

BUTYRIC ACID WITH NUTRIENT SYNERGISTS TO SUPPORT GUT HEALTH

Clinical Benefits[†]

- Butyrate, a short-chain fatty acid (SCFA), is the primary fuel for epithelial cells of the colon and helps to maintain intestinal barrier integrity.
- Tributyrin is a highly bioavailable form of butyrate, providing a superior half-life and increase in plasma levels compared to supplementation with sodium butyrate.
- The sustained increase in plasma levels of butyrate with tributyrin supplementation may allow for more systemic and epigenetic effects of butyrate.
- In addition to maintaining the intestinal barrier and reducing . intestinal inflammation, butyrate has also been associated with multiple metabolic effects, and may play a role in weight and glycemic control, as well as supporting insulin metabolism.
- Multiple models suggest tributyrin protects the liver and intestinal barrier from a variety of insults, including ethanol and bacterial toxins.

Butyric-Cal-Mag[™] supplies tributyrin, as ButyraGen[™] a butyrate generator. Upon breakdown by gut enzymes, it supplies the postbiotic butyrate, the primary fuel of colonic cells. Butyric acid is a naturally-occurring 4-carbon fatty acid formed in the healthy colon from the fermentation of dietary fiber by friendly bacteria. **Butyric-Cal-Mag™** also contains complementary antioxidants in the form of mixed carotenoids (a source of vitamin A), calcium and magnesium. In addition, this product provides pantothenic acid, necessary for the synthesis of acetyl CoA.¹ Inhibition of the acetyl CoA pathway has been associated with impaired butyrate synthesis.²

ButyraGen[™] – Tributyrin Complex

ButyraGen[™] is an innovative ingredient. With its ability to work as a direct butyrate generator, it is able to produce high levels of butyrate directly in the colon.

In pre-clinical studies of ButyraGen[™] Tributyrin Complex has been shown to:

- Generate butyrate and other short chain fatty acids³
- · Significantly lower gas production when compared to other prebiotics4
- Help reduce oxidative stress⁵



Butyric-Cal-Mag[™] available in a 60 capsule bottle (#7810)

Butyrate, a type of short-chain fatty acid (SCFA), is produced by commensal bacteria in the colon from the fermentation of dietary fiber, primarily indigestible plant polysaccharides and resistant starches. In addition to its well-recognized role as the preferred energy source for colonocytes, butyrate has now been shown to have a much broader physiological role that extends beyond the colon, influencing systemic metabolic and immune function, as well as reducing intestinal permeability and inflammation

Tributyrin contains three butyrate moieties esterified with glycerol, which is rapidly absorbed and hydrolyzed to butyrate when metabolized by pancreatic lipases. Found in honey and dairy products such as butter, tributyrin has several advantages when compared to supplementation with butyrate alone. Tributyrin is more bioavailable, is better tolerated, and allows for significantly higher plasma levels, with approximately three times the serum half-life (demonstrated in animal studies).⁶ Additionally, in contrast to tributyrin, it is not clear that oral butyrate reaches colonocytes, as most of it is taken up by enterocytes in the proximal intestine.⁷



(800) 231-5777

5245 Business Park Drive • Rosenberg, TX 77469 biotics@bioticsresearch.com • www.bioticsresearch.com

Tributyrin overcomes the limitations imposed by the short half-life of butyrate and has shown promising results for wide-ranging effects in experimental models. Tributyrin has been shown to prevent fat accumulation and support liver function compromised by alcohol toxicity, in part mediated through epigenetic mechanisms, including inhibition of histone deacetylases, and activation of PGC-1a expression, an essential inducer of mitochondrial biogenesis.⁸ Tributyrin also protects the liver from damage in response to lipopolysaccharide (LPS)-induced liver injury, an effect mediated through attenuation of several inflammatory mediators, including NF-KB, a critical regulator of inflammation.^{9,10} It has also been shown to prevent oxidative stress in the colon and preserve intestinal immune function in response to ethanol-induced injury.¹¹ Tributyrin has been shown to modulate PPARy and AMPK, with favorable effects on memory and cognitive function in animal models of memory impairment, consistent with the generally beneficial effect of SCFAs on the gut-brain axis.^{12,13} Activation of AMPK also appears to be one mechanism by which butyrate enhances intestinal barrier function, as AMPK activation increases the assembly of epithelial tight junctions.^{14,15} Protection from toxins, such as C. difficile toxins, also appears to be another mechanism by which butyrate reduces intestinal inflammation.¹⁶

Metabolic Health

In addition to its ability to help maintain intestinal barrier integrity and support immune function, butyrate has emerged as a potential link between diet and intestinal flora, and the dysbiosis-associated inflammation linked to both obesity and metabolic disturbances.^{17,18} The Western diet has been associated with a reduction in the richness and diversity of intestinal bacterial species, including a decrease in species known to synthesize butyrate. Metabolic syndrome, hypertension, type 2 diabetes, and obesity have all been associated with a decrease in the abundance of butyrateproducing bacteria, such as F. prausnitzii, and A. muciniphila, as well as reduced intestinal levels of butyrate.^{19,20,21} In a proof-of-concept study, supplementation of insulin resistant and overweight/obese participants with A. muciniphila reduced body weight, inflammation, and fat mass, while improving insulinemia and insulin resistance, effects likely related to the increase in butyrate synthesis.²² Furthermore, supplementation with butyrate directly has been associated with improvements in weight, glucose metabolism, and inflammation in a guadruple-blinded trial of pediatric obesity, further supporting the case for butyrate as a regulator of energy intake and metabolism.²³ Multiple mechanisms likely underlie these clinical benefits, including improved insulin sensitivity, upregulation of mitochondrial activity and fat oxidation, decreased energy intake, and stimulation of leptin expression.24,25,26

References

- Martinez DL, Tsuchiya Y, Gout I. Coenzyme A biosynthetic machinery in mammalian cells. Biochem Soc Trans. 2014 Aug42(4):1112-7.
- Singhal R, Donde H, Ghare S, et al. Decrease in acetyl-CoA pathway utilizing butyrate-producing bacteria is a key pathogen feature of alcohol-induced functional gut microbial dysbiosis and development of liver disease in mice. Gut Microbes. 2021 Jan-Dec;13(1):1946367.
- 3. ButyraGen Butyrate Generation." NutriScience Innovations, LLC. Self-Published Technical White Paper. June 21, 2022.
- ButvraGen Compared to Other Prebiotics," NutriScience Innovations, LLC, Self-Published Technical White Paper, March 7, 2022. 4 ButyraGen Reduces Oxidative Stress Study." NutriScience Innovations, LLC. Self-Published Technical White Paper. March 7, 2022. 5.
- Heidor R, Ortega JF, de Conti A, et al. Anticarcinogenic actions of tributyrin, a butyric acid prodrug. Curr Drug Targets. 2012 б.
- Dec;13(14):1720-9 van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. Obes Rev. 2022 Oct;23(10):e13498.
- Donde H, Ghare S, Joshi-Barve S, et al. Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury. Cell Mol Gastroenterol Hepatol. 2020;9(4):569-585.
- Miyoshi M, Sakaki H, Usami M, et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and 9. prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr. 2011 Apr;30(2):252-8.
- 10. Miyoshi M, Usami M, Kajita A, et al. Effect of Oral Tributyrin Treatment on Lipid Mediator Profiles in Endotoxin-Induced Hepatic Injury, Kobe J Med Sci. 2020 Dec 16:66(4):E129-E138
- Glueck B, Han Y, Cresci GAM. Tributyrin Supplementation Protects Immune Responses and Vasculature and Reduces Oxidative Stress in the Proximal Colon of Mice Exposed to Chronic-Binge Ethanol Feeding. J Immunol Res. 2018 Aug 19;2018:9671919.
- Belén Sanz-Martos A, Fernández-Felipe J, Merino B, Cano V, et al. Butyric Acid Precursor Tributyrin Modulates Hippocampal Synaptic Plasticity and Prevents Spatial Memory Deficits: Role of PPARy and AMPK. Int J Neuropsychopharmacol. 2022 Jun 2125(6):498-511.
- 13. van de Wouw M, Boehme M, Lyte JM, et al. Short-chain fatty acids: microbial metabolites that alleviate stress-induced braingut axis alterations. J. Physiol. 2018 Oct: 596(20):4923-4944
- eng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009 Sep;139(9):1619-25.
- Miao W, Wu X, Wang K, et al. Sodium Butyrate Promotes Reassembly of Tight Junctions in Caco-2 Monolayers Involving Inhibition of MLCK/MLC2 Pathway and Phosphorylation of PKCβ2. Int J Mol Sci. 2016 Oct 10;17(10):1696. 16. Fachi JL, Felipe JS, Pral LP, et al. Butvrate Protects Mice from Clostridium difficile-Induced Colitis through an HIF-1-Dependent
- Mechanism. Cell Rep. 2019 Apr 16;27(3):750-761.e7 17. Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? v. 2013 Dec;14(12):950-9
- Kaźmierczak-Siedlecka K, Marano L, Merola E, et al. Sodium butyrate in both prevention and supportive treatment of colorectal cancer. Front Cell Infect Microbiol. 2022 Oct 26;12:1023806.
- 19. Gradisteanu Pircalabioru G, Liaw J, et al. Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome-Associated Gut Microbiome. Int J Mol Sci. 2022 Jul 6;23(14):7509.
- 20. James MM, Pal N, Sharma P, et al. Role of butyrogenic Firmicutes in type-2 diabetes. J Diabetes Metab Disord. 2022 Jul 14.21(2).1873-1882
- Arora T, Tremaroli V. Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes. Front Endocrinol (Lausanne). 2021 Oct 19;12:761834. 22. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human
- volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096-1103. 23. Coppola S, Nocerino R, Paparo L, et al. Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial. JAMA
- Netw Open. 2022 Dec 1:5(12):e2244912
- Hong J, Jia Y, Pan Set al. Butyrate alleviates high fat diet-induced obesity through activation of adiponectin-mediat and stimulation of mitochondrial function in the skeletal muscle of mice. Oncotarget. 2016 Aug 30;7(35):56071-5 d pathway
- Li Z, Yi CX, Katiraei S, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut 2018 Jul:67(7):1269-1279
- 26. Soliman MM, Ahmed MM, Salah-Eldin AE, et al. Butyrate regulates leptin expression through different signaling pathways in adipocytes. J Vet Sci. 2011 Dec:12(4):319-23

Supplement Facts Serving Size: 2 Capsules Servings Per Container: 30

	Amount Per Serving	% Daily Value
Vitamin A (as natural mixed carotenoids and acetate)	975 mcg RAE	108%
Pantothenic Acid (as calcium pantothenate)	16.7 mg	334%
Calcium (as calcium citrate)	40 mg	3%
Magnesium (as magnesium citrate)	40 mg	10%
ButyraGen™ Tributyrin Complex	1,000 mg	*
*Daily Value not established		

Other ingredients: Capsule shell (gelatin and water), gum arabic, guar fiber, rosemary extract, silica and cellulose

This product is gluten and dairy free.

ButvraGen[™] is a trademark of NutriScience Innovations I I C

RECOMMENDATION: Two (2) capsules as a dietary supplement or as otherwise directed by a healthcare professional.

> **KEEP OUT OF REACH OF CHILDREN** Store in a cool, dry area. Sealed with an imprinted safety seal for your protection.



(800) 231-5777

5245 Business Park Drive • Rosenberg, TX 77469 biotics@bioticsresearch.com • www.bioticsresearch.com